On September 4, 2025, NKGen Biotech, Inc. completed the acquisition of a majority stake (65%) in NKMax Co., Ltd. for approximately $17 million, purchasing 46.4 million shares at $0.36 each, enhancing its control over NKMax’s manufacturing and intellectual properties.